Associated Papers
Molecular insights for the tumor suppressor role of SPOP in prostate cancer.
Yan P et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2026
Ubiquitination-directed cytosolic DNA degradation governs cGAS-STING-mediated immune response to DNA damage.
Li L et al.
Cancer Cell, 2026
Systematic Characterization of Cancer-Associated SPOP Mutants Reveals Novel and Reprogrammable Degradative Activities.
Caldwell AG et al.
Chembiochem : a European Journal of Chemical Biology, 2026
Systematic characterization of cancer-associated SPOP mutants reveals novel and reprogrammable degradative activities.
Caldwell AG et al.
Biorxiv : the Preprint Server for Biology, 2025
TRIM24-mediated K27-linked ubiquitination of ULK1 alleviates energy stress-induced autophagy and promote prostate cancer growth in the context of SPOP mutation.
Chen S et al.
Cell Death and Differentiation, 2025
Deep Sequencing Reveals Novel Mutations in Androgen Receptor-Related Genes in Prostate Cancer.
Pedroza-Torres A et al.
International Journal of Molecular Sciences, 2025
SPOP and MMR/MSI alterations in prostate cancer: relationship with PD-L1, TILs and AR expression.
Fiorentino V et al.
Pathologica, 2025
Cancer-associated SPOP mutations enlarge nuclear size and facilitate nuclear envelope rupture upon farnesyltransferase inhibitor treatment.
Wang Z et al.
The Journal of Clinical Investigation, 2025
SPOP-dependent destabilization of SYT12 in a GSK-3β-dependent manner in papillary thyroid cancer cells.
Zhou S et al.
Clinical and Experimental Medicine, 2025
Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population.
Arun AS et al.
The Pharmacogenomics Journal, 2025
Cul3 substrate adaptor SPOP targets Nup153 for degradation.
Ong JY et al.
Molecular Biology of the Cell, 2025
Decoding the functional impact of the cancer genome through protein-protein interactions.
Fu H et al.
Nature Reviews. Cancer, 2025
Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence.
Arce-Gallego S et al.
Cell Reports. Medicine, 2025
Updates on SPOP Gene Mutations in Prostate Cancer and Computational Insights From TCGA cBioPortal Database.
Zakari S et al.
Scientifica, 2025
Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression.
Diossy M et al.
Npj Precision Oncology, 2024
ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance.
Lee CJ et al.
Cell Death & Disease, 2024
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression without inducing homologous recombination deficiency.
Szallasi Z et al.
Research Square, 2024
Deficiency in SPOP-mediated ubiquitination and degradation of TIAM1 promotes gastric cancer progression.
Liu F et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease, 2024
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.
Geng C et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer.
Zivanovic A et al.
Nar Cancer, 2023
Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers.
Cavalcante L et al.
Jco Precision Oncology, 2023
SPOP targets the immune transcription factor IRF1 for proteasomal degradation.
Schwartz I et al.
Elife, 2023
Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease Progression.
Bang S et al.
Cancers, 2023
Cul3 substrate adaptor SPOP targets Nup153 for degradation.
Ong JY et al.
Biorxiv : the Preprint Server for Biology, 2023
Mass spectrometry-based targeted proteomics for analysis of protein mutations.
Lin TT et al.
Mass Spectrometry Reviews, 2023
CHD1, a multifaceted epigenetic remodeler in prostate cancer.
Li H et al.
Frontiers in Oncology, 2023
Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis.
Rezaeian AH et al.
Advances in Protein Chemistry and Structural Biology, 2023
Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry.
White JA et al.
Cancer Research Communications, 2022
ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression.
Fan Y et al.
Cell Death and Differentiation, 2022
SPOP mutations promote p62/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer.
Shi Q et al.
Cell Death and Differentiation, 2022